Literature DB >> 33200360

Epidemiology of Virus Infection and Human Cancer.

Chien-Jen Chen1, San-Lin You2, Wan-Lun Hsu3, Hwai-I Yang3, Mei-Hsuan Lee4, Hui-Chi Chen3, Yun-Yuan Chen5, Jessica Liu6,7, Hui-Han Hu8, Yu-Ju Lin4, Yu-Ju Chu9, Yen-Tsung Huang10, Chun-Ju Chiang11, Yin-Chu Chien3.   

Abstract

Seven viruses including the Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), Kaposi's sarcoma herpes virus (KSHV), human immunodeficiency virus, type-1 (HIV-1), human T cell lymphotrophic virus, type-1 (HTLV-1), and human papillomavirus (HPV) have been classified as Group 1 human carcinogens by the International Agency for Research on Cancer (IARC). The conclusions are based on the findings of epidemiological and mechanistic studies. EBV, HPV, HTLV-1, and KSHV are direct carcinogens; HBV and HCV are indirect carcinogens through chronic inflammation; and HIV-1 is an indirect carcinogen through immune suppression. Some viruses may cause more than one cancer, while some cancers may be caused by more than one virus. However, only a proportion of persons infected by these oncogenic viruses will develop specific cancers. A series of studies have been carried out to assess the viral, host, and environmental cofactors of EBV-associated nasopharyngeal carcinoma, HBV/HCV-associated hepatocellular carcinoma, and HPV-associated cervical carcinoma. Persistent infection, high viral load, and viral genotype are important risk predictors of these virus-caused cancers. Risk calculators incorporating host and viral risk predictors have been developed for the prediction of long-term risk of hepatocellular carcinoma, nasopharyngeal carcinoma and cervical cancer. These risk calculators are useful for the triage and clinical management of infected patients. Both clinical trials and national programs of immunization, antiviral therapy and screening have demonstrated a significant reduction in the incidence of cancers caused by HBV, HCV, and HPV. Future research on gene-gene and gene-environment interactions of oncogenic viruses and the human host using large-scale longitudinal studies with serial measurements of biosignatures are in urgent need.

Entities:  

Keywords:  Cancer; EBV; Epidemiology; HBV; HCV; HIV; HPV; HTLV-I; KSHV

Mesh:

Year:  2021        PMID: 33200360     DOI: 10.1007/978-3-030-57362-1_2

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  6 in total

1.  Cancer among kidney transplant recipients >20 years after transplantation: post-transplant lymphoproliferative disorder remains the most common cancer type in the ultra long-term.

Authors:  Julia D Fuhrmann; Kristyna Valkova; Seraina von Moos; Rudolf P Wüthrich; Thomas F Müller; Thomas Schachtner
Journal:  Clin Kidney J       Date:  2022-01-13

2.  Unlocking the Role of a Genital Herpesvirus, Otarine Herpesvirus 1, in California Sea Lion Cervical Cancer.

Authors:  Alissa C Deming; James F X Wellehan; Kathleen M Colegrove; Ailsa Hall; Jennifer Luff; Linda Lowenstine; Pádraig Duignan; Galaxia Cortés-Hinojosa; Frances M D Gulland
Journal:  Animals (Basel)       Date:  2021-02-13       Impact factor: 2.752

3.  Risk of Non-Hodgkin Lymphoma among Patients with Hepatitis B Virus and Hepatitis C Virus in Taiwan: A Nationwide Cohort Study.

Authors:  Yung-Rung Lai; Ya-Lan Chang; Chiu-Hsiang Lee; Tung-Han Tsai; Kuang-Hua Huang; Chien-Ying Lee
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

4.  Exploring the Multicomponent Synergy Mechanism of Yinzhihuang Granule in Inhibiting Inflammation-Cancer Transformation of Hepar Based on Integrated Bioinformatics and Network Pharmacology.

Authors:  Jingyuan Zhang; Zhihong Huang; Xinkui Liu; Chao Wu; Wei Zhou; Peizhi Ye; Antony Stalin; Shan Lu; Yingying Tan; Zhishan Wu; Xiaotian Fan; Xiaomeng Zhang; Miaomiao Wang; Bingbing Li; Guoliang Cheng; Yanfang Mou; Jiarui Wu
Journal:  Biomed Res Int       Date:  2022-03-18       Impact factor: 3.411

Review 5.  mRNA vaccines in the prevention and treatment of diseases.

Authors:  Yangzhuo Gu; Jiangyao Duan; Na Yang; Yuxin Yang; Xing Zhao
Journal:  MedComm (2020)       Date:  2022-08-25

Review 6.  Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors.

Authors:  Alejandro Olivares-Hernández; Luis Figuero-Pérez; José Pablo Miramontes-González; Álvaro López-Gutiérrez; Rogelio González-Sarmiento; Juan Jesús Cruz-Hernández; Emilio Fonseca-Sánchez
Journal:  Life (Basel)       Date:  2021-12-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.